Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- Volociximab M200 ?5-?1 ?5?1Fc ITGA-5 ITGB-1 VLA4 VLA5 CD49-E CD-49E CD-29 antiintegrin anti-body IgG-4? IgG4-?
- Product Overview:
Integrin ?5?1 is a cell adhesion receptor that is involved in the attachment of cells to the extracellular matrix (ECM) and cell-cell interactions.{59572} It is composed of a heterodimer of two integrin subunits, integrin ?5, also known as CD49E, that binds to the RGD sequence and central cell-binding domain of fibronectin, and integrin ?1, also known as CD29, that interacts with the cytoskeleton and intracellular signaling molecules.{66151,59653} Integrin ?5?1 localizes to the cell surface and mediates outside-in and inside-out signaling cascades that regulate angiogenesis and cell differentiation, as well as migration, development, and hematopoiesis.{66152,59572} An anti-integrin ?5?1 monoclonal antibody inhibits tube formation and proliferation of human umbilical vein endothelial cells (HUVECs) in vitro and prevents laser-induced choroidal neovascularization in a cynomolgus monkey model of macular degeneration.{66153} Integrin ?5?1 levels are increased in tumoral neovasculature.{66154} Cayman’s Integrin ?5?1 Chimeric Monoclonal Antibody was produced recombinantly from the original M200 antibody sequence and can be used for ELISA, flow cytometry (FC), immunofluorescence (IF), and immunohistochemistry (IHC) applications. The M200 antibody was generated by fusing human IgG4? constant domains to the antigen-binding domain of a mouse anti-integrin ?5?1 monoclonal antibody.{62892}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.